RxDoctor Payments Data

Arun Sehgal, MD

Internal Medicine · Ramsey, NJNPI 1326017799

Payments from drug & device makers

$612in general payments, 2019–2025

Across 28 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$125
  • Optinose US, Inc.$110
  • Astellas Pharma US Inc$55
  • Teva Pharmaceuticals USA, Inc.$54
  • Lilly USA, LLC$41
  • Novartis$39
  • plus $188 from 10 others

What the payments were for

  • Food & beverage$612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$612 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$429,276
Medicare patients
750
Services billed
4,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban691$265,074
ProcritEpoetin Alfa54$189,470
VraylarCariprazine Hcl75$53,753
RetacritEpoetin Alfa-Epbx22$36,419
XareltoRivaroxaban98$28,076
SantylCollagenase Clostridium Hist.59$27,351
NuplazidPimavanserin Tartrate11$27,341
EpogenEpoetin Alfa33$22,489
JanuviaSitagliptin Phosphate49$20,205
TrulicityDulaglutide15$19,817
Divalproex Sodium288$16,606
EntrestoSacubitril/Valsartan46$14,449
JardianceEmpagliflozin35$14,227
JanumetSitagliptin Phos/Metformin Hcl20$13,996
FarxigaDapagliflozin Propanediol31$12,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Retacrit$13$301,493713 claims
Johnson & JohnsonProcrit, Xarelto$30$217,546152 claims
AbbVieVraylar$27$53,75375 claims
MerckJanuvia, Janumet$15$34,20169 claims
AstraZenecaFarxiga, Brilinta$125$24,87356 claims
Lilly USA, LLCTrulicity$41$19,81715 claims
NovartisEntresto$39$14,44946 claims
GSKIncruse Ellipta$29$5,00014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Ramsey

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →